Table 3.

Adverse events during the study.

	Total (n = 243)	CKD-495 75 mg (n = 54)	CKD-495 150 mg (n = 48)	Placebo (n = 48)	Stillen 60 mg (n = 48)	Rebamipide100 mg (n = 45)	p valuea
	n (%) [case]	n (%) [case]	n (%) [case]	n (%) [case]	n (%) [case]	n (%) [case]
Gastrointestinal disorders	12 (4.94) [16]	3 (5.56) [5]	2 (4.17) [2]	1 (2.08) [3]	2 (4.17) [2]	4 (8.89) [4]	0.6742a
Gastrooesophageal reflux disease	4 (1.65) [4]	—	2 (4.17) [2]	—	1 (2.08) [1]	1 (2.22) [1]	0.3779a
Diarrhea	3 (1.23) [4]	1 (1.85) [2]	—	1 (2.08) [1]	—	1 (2.22) [1]	0.8420a
Dyspepsia	3 (1.23) [3]	1 (1.85) [1]	—	—	1 (2.08) [1]	1 (2.22) [1]	0.8420a
Abdominal distension	2 (0.82) [2]	1 (1.85) [1]	—	1 (2.08) [1]	—	—	1.0000a
Erosive duodenitis	1 (0.41) [1]	1 (1.85) [1]	—	—	—	—	1.0000a
Eructation	1 (0.41) [1]	—	—	1 (2.08) [1]	—	—	0.7778a
Gastric ulcer	1 (0.41) [1]	—	—	—	—	1 (2.22) [1]	0.1852a
General disorders and administration site conditions	1 (0.41) [1]	—	1 (2.08) [1]	—	—	—	0.7778a
Chest discomfort	1 (0.41) [1]	—	1 (2.08) [1]	—	—	—	0.7778a
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1 (0.41) [1]	—	—	1 (2.08) [1]	—	—	0.7778a
Gastrointestinal submucosal tumour	1 (0.41) [1]	—	—	1 (2.08) [1]	—	—	0.7778a
Nervous system disorders	1 (0.41) [1]	—	1 (2.08) [1]	—	—	—	0.7778a
Dizziness	1 (0.41) [1]	—	1 (2.08) [1]	—	—	—	0.7778a
Skin and subcutaneous tissue disorders	1 (0.41) [1]	—	—	—	1 (2.08) [1]	—	0.7778a
Cold sweat	1 (0.41) [1]	—	—	—	1 (2.08) [1]	—	0.7778a
Total	16 (6.58) [20]	3 (5.56) [5]	4 (8.33) [4]	2 (4.17) [4]	3 (6.25) [3]	4 (8.89) [4]	0.8914a

^aFisher's exact test for comparison of proportions between the groups.